^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BCMA CAR-T cell therapy

    i
    Other names: BCMA CAR-T cell therapy, BCMA CAR-T cells, BCMA-Targeted prime CAR-T cell therapy
    Associations

    News

    Trials
    Company:
    Chongqing Precision Biotech
    Drug class:
    BCMA-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    over1year
    a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=80, Recruiting, Chongqing Precision Biotech Co., Ltd | Trial completion date: Jul 2023 --> Jul 2024 | Trial primary completion date: Jan 2023 --> Dec 2023
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    IL6 (Interleukin 6)
    |
    BCMA CAR-T cell therapy
    over1year
    Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=40, Recruiting, Chongqing Precision Biotech Co., Ltd | Trial completion date: Jul 2023 --> Jul 2024 | Trial primary completion date: Dec 2022 --> Dec 2023
    Trial completion date • Trial primary completion date
    |
    IL6 (Interleukin 6)
    |
    BCMA CAR-T cell therapy
    over3years
    a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=80, Recruiting, Chongqing Precision Biotech Co., Ltd | Active, not recruiting --> Recruiting
    Clinical • Enrollment open • CAR T-Cell Therapy
    |
    IL6 (Interleukin 6)
    |
    BCMA CAR-T cell therapy